bexarotene has been researched along with Leukemia, Promyelocytic, Acute in 5 studies
*Leukemia, Promyelocytic, Acute: An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berger, E; Boehm, MF; Davies, JA; Heyman, RA; Mais, DE; McClurg, MR; Suto, CM; Wagoner, M; Zhang, L; Zhi, L | 1 |
| Abboud, CN; Cashen, AF; Dipersio, JF; Jacoby, M; Niu, H; Pusic, I; Schroeder, MA; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Welch, JS; Westervelt, P | 1 |
| Andreadis, C; Bagg, A; Carroll, M; Goldstein, SC; Goradia, A; Kemner, A; Loren, AW; Luger, SM; Mato, AR; Perl, AE; Porter, DL; Potuzak, M; Schuster, SJ; Stadtmauer, EA; Swider, C; Thompson, JE; Tsai, DE; Vogl, DT | 1 |
| DiNardo, CD; Forfia, P; Ky, B; Loren, A; Luger, S; Mato, A; Tsai, DE; Vogl, DT | 1 |
| Cohen, MH; Flamm Honig, S; Hirschfeld, S; Ibrahim, A; Johnson, JR; O'Leary, JJ; Pazdur, R; White, RM; Williams, GA | 1 |
2 trial(s) available for bexarotene and Leukemia, Promyelocytic, Acute
| Article | Year |
|---|---|
A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML.
Topics: Administration, Oral; Aged; Aged, 80 and over; Animals; Anticarcinogenic Agents; Antimetabolites, Antineoplastic; Azacitidine; Bexarotene; Decitabine; Drug Administration Schedule; Drug Therapy, Combination; Female; Gene Expression; Gene Expression Profiling; Humans; Injections, Intravenous; Leukemia, Promyelocytic, Acute; Male; Mice; Middle Aged; Receptors, Retinoic Acid; Recurrence; Retinoic Acid Receptor alpha; Retinoid X Receptor alpha; Tetrahydronaphthalenes; Tumor Cells, Cultured | 2014 |
A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bexarotene; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Maximum Tolerated Dose; Middle Aged; Retinoid X Receptors; Tetrahydronaphthalenes | 2008 |
3 other study(ies) available for bexarotene and Leukemia, Promyelocytic, Acute
| Article | Year |
|---|---|
Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells.
Topics: Apoptosis; Bexarotene; Binding, Competitive; Cell Line; Drug Design; Humans; Leukemia, Promyelocytic, Acute; Ligands; Niacin; Nicotinic Acids; Receptors, Retinoic Acid; Retinoid X Receptors; Retinoids; Structure-Activity Relationship; Tetrahydronaphthalenes; Transcription Factors; Transglutaminases; Tumor Cells, Cultured | 1995 |
Differentiation syndrome in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene.
Topics: Antineoplastic Agents; Bexarotene; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Pericardial Effusion; Retinoid X Receptors; Syndrome; Tetrahydronaphthalenes | 2008 |
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.
Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Arsenic Trioxide; Arsenicals; Bexarotene; Breast Neoplasms; Drug Approval; Female; Humans; Leukemia, Promyelocytic, Acute; Lymphoma, T-Cell, Cutaneous; Nitriles; Oxides; Paclitaxel; Tamoxifen; Tetrahydronaphthalenes; Triazoles; United States; United States Food and Drug Administration | 2001 |